

## Preclinical Experiments Support Recent Clinical Switch to Delivered Dose During Methacholine Bronchoprovocation Testing

O. Schmid<sup>1,2</sup>, W. Möller<sup>1,2</sup>, A. Stelzl<sup>1,2</sup>, J. Lund<sup>2</sup>, A. Ö. Yildirim<sup>1</sup>, S. Krauss-Etschmann<sup>2</sup>, A. Robichaud<sup>3</sup>

<sup>1</sup>Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München (HMGU), Neuherberg/Munich, Germany,

<sup>2</sup>Research Center Borstel (RBC), Borstel, Germany, <sup>3</sup>SCIREQ Scientific Respiratory Equipment, Inc., Montreal, Quebec, Canada


### Background & Objectives

- Airway hyperresponsiveness (AHR) testing is a clinically used, central element of asthma diagnostics.
- The **methacholine concentration** of inhaled aerosol causing a 20% decrease in forced expiratory volume in 1 second (**PC20**) has typically been used to quantify the degree of AHR.
- The most recent standard of the European Respiratory Society (ERS) - endorsed by the American Thoracic Society (ATS) - recommends the effective **delivered dose of methacholine (PD20)**, rather than concentration (PC20) (Coates et al., 2017)
- Expectation: PD20 (not PC20) allows for comparison of AHR results from different aerosol devices or protocols.
- Objectives:**
  - Assess the validity of this expectation in mouse experiments
  - Evaluate the use of the lung-deposited dose

### Methods

- Healthy C57BL/6 mice (age:8-14 w); male (27-33g), female (19-22g)
- Anaesthesia, oral intubation, mechanical ventilation (flexiVent; emka TECHNOLOGIES-SCIREQ Inc.)
- AHR assessments to increasing concentrations of aerosolized methacholine (0 – 25 mg/mL)
  - At different times: between 2013 – 2017
  - In two different laboratories: CPC, RBC
- Two aerosol delivery protocols: **EMKA** (standard) and **HMGU** (maximized delivery)
  - Changes in respiratory resistance: forced oscillation technique (single frequency, 2.5Hz)
  - Delivered (inhaled) aerosol dose: gravimetric determination
  - Lung-deposited dose: concentration of a fluorescent tracer in lung homogenates

### Experimental Set-up




System for intubated ventilated aerosol delivery (methacholine) and lung function measurement in mice (flexiVent, EMKA)


### Aerosol Delivery Protocols

Parameters	EMKA (standard)	HMGU (maximized delivery)
Respiratory frequency (bpm)	150 bpm	120 bpm
Tidal Volume	10 mL/kg	400 µL
Inspiratory:expiratory ratio	2:3	2:1
PEEP (cmH <sub>2</sub> O)	3	3
Nebulizer ID	Aeroneb Pro/#204	Aeroneb Lab/#093
Droplet volume median diameter (µm)	4.0 – 6.0	3.5 - 4.0
Output rate – continuous (µL/min)	500	250
Nebulizer duty cycle (%)	50	100
Nebulizer on-time/breath (ms)	80	20
Nebulized volume (µL)	10	10
Nebulization time/challenge (s)	10	70
Mass median droplet diameter (µm)	5.07	3.94
Delivery efficiency – dose delivered: loaded dose ratio (%)	8.4 ± 0.7	40.4 ± 1.0

### Results



### Methacholine Airway Responsiveness (AHR)



Attenuation of protocol-specific differences

### Conclusions

- Variations in aerosol delivery protocol affect the dose (delivered & deposited) of methacholine in mice.
- As expected, expressing airway hyperresponsiveness (AHR) results in terms of dose allows direct study comparisons between laboratories employing different equipment and aerosol delivery protocols.
- The present results thus **support the updated clinical ERS standard recommending the dose – rather than concentration** - as measure for bronchial methacholine challenge testing.
- While the delivered dose helps to attenuate protocol-specific differences, the lung-deposited dose could represent a better metrics for measuring AHR, especially when adjusted to the subject's weight.
- As clinically recommended, **the dose of methacholine (delivered or deposited) should be used to standardize preclinical (and clinical) AHR testing.**

#### References:

Robichaud, A., Fereydoonza, L. and Schuessler, T. F. (2015). Delivered dose estimate to standardize airway hyperresponsiveness assessment in mice. *Am J Physiol Lung Cell Mol Physiol* 308, L837-L846.  
Coates, A. L., S. D. Dell, D. W. Cockcroft, and G. M. Gauvreau. (2017). The PD20 but not the PC20 in a methacholine challenge test is device independent. *Ann Allergy Asthma Immunol* 118 (4):508-50